Sign In
Buy ABMD
$381.02
+0 (+0%)
At Close: Mar 20, 2023
Could This Recently IPOed Medical Device Maker Make You Rich?
07:07am, Saturday, 03'rd Jul 2021
Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.
Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod
10:18am, Wednesday, 30'th Jun 2021
Abiomed's (ABMD) Impella RP with SmartAssist gets the highest level of approval from the FDA for treatment of right heart failure.
FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure
08:03am, Tuesday, 29'th Jun 2021
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed's (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as sa
Abiomed (ABMD) Enters Overbought Territory
09:01am, Tuesday, 22'nd Jun 2021
Abiomed (ABMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio
11:17am, Thursday, 03'rd Jun 2021
Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.
Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients
08:03am, Tuesday, 01'st Jun 2021
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed's product portfolio to expand options fo
Abiomed to Shareholders: Patience Please, Growth Is On The Way.
07:45am, Tuesday, 04'th May 2021
Despite record revenue for its latest quarter, the medical device maker's shares sank 8% following its earnings release. But its next stage of growth is coming.
The End of the Pandemic Will Mean a Major Boost for These 2 Buy-and-Hold Stalwarts
06:15am, Tuesday, 04'th May 2021
People will be getting back to their regular routines when it comes to medical and dental care.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4
02:17pm, Thursday, 29'th Apr 2021
ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.
Abiomed's (ABMD) CEO Mike Minogue on Q4 2021 Results - Earnings Call Transcript
02:10pm, Thursday, 29'th Apr 2021
Abiomed's (ABMD) CEO Mike Minogue on Q4 2021 Results - Earnings Call Transcript
Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates
09:46am, Thursday, 29'th Apr 2021
Abiomed (ABMD) delivered earnings and revenue surprises of 12.73% and 4.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Dr. Paula A. Johnson Joins Abiomed Board of Directors
08:03am, Wednesday, 28'th Apr 2021
DANVERS, Mass.--(BUSINESS WIRE)--Dr. Paula Johnson joins the Abiomed Board of Directors
ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?
12:01pm, Friday, 23'rd Apr 2021
Strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal fourth quarter as well.
Abiomed: Valuation Drivers Justify The Premium Over Peers
06:39pm, Wednesday, 21'st Apr 2021
Abiomed shares continue their positive outlook, driven by sales momentum in the Impella 5.0 & 5.5 platforms. Excellent balance sheet management with no debt load signals, high free cash conversion, an
First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella
08:03am, Thursday, 15'th Apr 2021
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that
